Andrew J. Stewart - Feb 28, 2024 Form 4 Insider Report for Bausch & Lomb Corp (BLCO)

Role
Officer
Signature
/s/ Debra E. Levin, attorney-in-fact
Stock symbol
BLCO
Transactions as of
Feb 28, 2024
Transactions value $
$0
Form type
4
Date filed
3/1/2024, 04:35 PM
Previous filing
Apr 26, 2023
Next filing
Apr 26, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BLCO Common Shares, No Par Value Award $0 +16.8K +50.61% $0.00 49.9K Feb 28, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BLCO Non-Qualified Stock Options (right to purchase) Award $0 +50.8K $0.00 50.8K Feb 28, 2024 Common Shares, No Par Value 50.8K $16.85 Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the grant of restricted stock units ("RSUs") under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (as amended and restated, the "Plan") which are scheduled to vest one-third on each of the first three anniversaries of the date of grant, subject generally to the reporting person's continued service and the terms of the Plan and the applicable award agreement thereunder. Vested RSUs are settled in common shares, no par value, of Bausch + Lomb Corporation.
F2 Reflects the grant of stock options to purchase common shares under the Plan.
F3 The stock options are generally scheduled to vest and become exercisable in equal installments on each of the first three anniversaries of the grant date, subject to the terms of the applicable award agreement.
F4 The stock options will expire on the tenth anniversary of the grant date.

Remarks:

The Reporting Person's title as an officer of the Issuer is President, Global Pharmaceuticals and International Consumer.